News

June 22, 2018June 22, 2018

Opioid Use May Contribute to Imbalances in the Gut and Spur Inflammation, Studies Find

News

Extended use of opioids promotes imbalances in the gut microbiome and triggers changes that worsen inflammation in the intestine, according to results of studies in a mouse model of colitis ... Read more

June 20, 2018June 20, 2018

Patient Concerns Over Effects of IBD Therapies on Reproductive Health Not Adequately Addressed, Study Reports

News

Women’s concerns over taking inflammatory bowel disease (IBD) medications during their reproductive years are not being satisfactorily addressed by physicians, according to a study that analyzed relevant social media posts. ... Read more

June 18, 2018June 18, 2018

FDA OKs for Use Noninvasive Stool Sample Test to Help Diagnose IBD

News

Bühlmann Laboratories has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its noninvasive fCAL Elisa test, which uses a stool sample to help diagnose inflammatory bowel disease (IBD). fCAL ... Read more

June 15, 2018June 15, 2018

Protein Complex May Offer Way of Limiting Inflammatory Reactions, Study Suggests

News

New research unveils how two molecules, protein complexes called S100A8 and S100A9, are regulated in order to limit an inflammatory responses to sites where they are needed, preventing the spread ... Read more

June 13, 2018June 13, 2018

Remicade Eases Anxiety, Improves Quality of Life for Some Crohn’s Patients, China Study Finds

News

Remicade (infliximab) significantly benefitted the mental health of patients newly diagnosed with Crohn’s disease who had responded to the treatment, improving their perceptions of their illness and quality of life, and lowering anxiety levels, a ... Read more

June 11, 2018June 11, 2018

Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies

News

Microbiotica, a company spun out of the Wellcome Sanger Institute, recently established a multiyear collaboration agreement with Genentech to discover, develop, and commercialize biomarkers, targets, and therapies for inflammatory bowel disease (IBD). ... Read more

June 8, 2018June 8, 2018

Stelara Reduces Risk of Hospitalization, Surgery for Crohn’s Patients, New Phase 3 Data Show

News

Stelara (ustekinumab) can reduce the risk of Crohn’s disease-related hospitalization and surgery, according to new two-year Phase 3 results announced by Janssen, the therapy’s maker. This new analysis of long-term ... Read more

June 6, 2018June 6, 2018

Eisai’s Small Molecule Analog Reduced Inflammation and Injury in Mice with IBD, Study Shows

News

A small molecule analog developed by Eisai, called ER-464195-01, may be a potential therapy for patients with inflammatory bowel disease (IBD) by reducing infiltration of inflammatory cells, according to researchers. Their ... Read more

June 4, 2018June 4, 2018

Patients with IBD More Likely to Develop Parkinson’s Disease, Study Suggests

News

Patients with inflammatory bowel disease (IBD) have a 22% higher risk of developing Parkinson’s disease, a large-scale observational study suggests. The study, “Inflammatory bowel disease increases the risk of Parkinson’s ... Read more

June 1, 2018June 1, 2018

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved the oral therapy Xeljanz (tofacitinib), by Pfizer, to treat adults with moderately to severely active ulcerative colitis (UC), the company announced. The treatment regimen calls ... Read more